{
  "nctId": "NCT03656783",
  "briefTitle": "Effects of Biktarvy on CFR in Stable HIV Patients",
  "officialTitle": "Effects of Biectegravir-Emtricitabine-Tenofovir Alafenamide on Coronary Flow Reserve in Stable HIV Patients (B/F/TAF-CFR) - Pilot Study",
  "protocolDocument": {
    "nctId": "NCT03656783",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-09-12",
    "uploadDate": "2022-11-09T09:23",
    "size": 472622,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03656783/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 25,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-09-14",
    "completionDate": "2021-09-15",
    "primaryCompletionDate": "2021-09-15",
    "firstSubmitDate": "2018-08-31",
    "firstPostDate": "2018-09-04"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nPatients with HIV on abacavir/lamivudine/dolutegravir STR regimens for at least 1 year fulfilling the following inclusion criteria:\n\n1. age ≥ 45 years for men and ≥ 55 years for women;\n2. at least one coronary risk factor including smoking, dyslipidemia, hypertension, obesity (BMI \\>30) or diabetes, or a calculated 10-year risk of heart attack of 7.5% or higher;\n3. HIV RNA \\< 200 copies/mL at last clinical measurement, done within the past 12 months prior to screening, with no intervening HIV RNA \\> 200;\n4. Screening HIV RNA \\< 50 copies/mL, CBC, and chemistries that, in the judgment of the investigator, do not preclude the use of Biktarvy.\n\nExclusion Criteria:\n\n1. patients not fulfilling inclusion criteria;\n2. unstable HIV disease or other medical condition that, in the opinion of the investigator, would interfere with the conduct of the study;\n3. history of cardiomyopathy (LVEF \\<40%) or significant valvular heart disease;\n4. cirrhosis;\n5. end stage renal disease on dialysis;\n6. uncontrolled hypertension (defined as SBP \\>200 or DBP \\>110);\n7. pregnancy;\n8. Patients requiring medications contraindicated with the components of B/F/TAF;\n9. Patients on active treatment for severe asthma or severe COPD.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "95 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Global CFR",
        "description": "Change in global coronary flow reserve, as measured by PET imaging at baseline and 24 weeks after initiation of B/F/TAF therapy.\n\nCoronary flow reserve (CFR), the ratio of peak vasodilator stress to rest myocardial blood flow (MBF), represents the maximal ability to augment coronary flow and myocardial perfusion. Absolute MBF was computed from the rest and stress myocardial perfusion PET images using commercially available software (Corridor4DM; Ann Arbor, Michigan) and a two-compartment tracer kinetic model. Impaired MBFR is defined as a ratio of \\<2.0, which is associated with increased cardiovascular risk.",
        "timeFrame": "baseline and week 24"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Peak Stress Global MBF",
        "description": "Change (from baseline) in peak-stress global myocardial blood flow (in mL/min/g) at 24 weeks after initiation of B/F/TAF.\n\nAbsolute MBF was computed from the rest and stress myocardial perfusion PET images using commercially available software (Corridor4DM; Ann Arbor, Michigan) and a two-compartment tracer kinetic model. Impaired stress MBF is defined as \\<1.8 mL/min/g and is associated with increased cardiovascular risk.",
        "timeFrame": "baseline and 24 weeks"
      },
      {
        "measure": "Change in Serum Biomarkers of Inflammation (Hs-CRP (in mg/L))",
        "description": "Change in serum biomarkers of inflammation (hs-CRP (in mg/L)) at 24 weeks after initiation of B/F/TAF.\n\nSerum biomarkers of inflammation (high sensitivity C-reactive protein) were measured. hs-CRP \\> 1 mg/L are considered abnormal and associated with increased cardiovascular risk.",
        "timeFrame": "Baseline and 24 weeks"
      },
      {
        "measure": "Change in Myocyte Injury and Strain (hs Troponin (in ng/L))",
        "description": "Change in Myocyte Injury and Strain (hs Troponin (in ng/L)) at 24 weeks after initiation of B/F/TAF.\n\nSerum biomarkers of myocardial injury/strain (high sensitivity troponin) were measured. hs-troponin \\>14 ng/L are considered abnormal and associated with increased cardiovascular risk.",
        "timeFrame": "Baseline and 24 weeks"
      },
      {
        "measure": "Change in Myocyte Injury and Strain (NT-proBNP (in pg/mL))",
        "description": "Change in Myocyte Injury and Strain (NT-proBNP (in pg/mL)) at 24 weeks after initiation of B/F/TAF.\n\nSerum biomarkers of myocardial injury/strain (NT-pro-BNP) were measured. NT-proBNP \\> 100 pg/mL are considered abnormal and associated with increased cardiovascular risk.",
        "timeFrame": "Baseline and 24 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 4,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 34,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:20.162Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}